Prolidase deficiency, an inherited enzymatic disease, may cause combined pulmonary fibrosis and emphysema (CPFE) syndrome in adulthood, a case study suggests. The report, “Prolidase deficiency: a new genetic cause of combined pulmonary fibrosis and emphysema syndrome in the adult,” was published in the European…
News
A high number of bacteria in the lungs of people with idiopathic pulmonary fibrosis (IPF) is linked to disease progression and to an increased risk of mortality, a study found. The study, “Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and…
A new technique to create lung cells from other, more easily accessible cell types could be useful for understanding diseases like idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The technique was described in an article, “Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity…
The European Patent Office (EPO) has issued a “notice of intent” to grant a patent to MN-001 (tipelukast), MediciNova’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF). Once issued, the patent will…
People with idiopathic pulmonary fibrosis have shorter telomeres — the protective caps at the end of chromosomes — but shortening may occur prior to disease onset. The study with that finding, “From organ to cell: Multi-level telomere length assessment in patients with idiopathic pulmonary fibrosis,” was published…
Statins, a class of medications widely prescribed to lower cholesterol levels and prevent heart disease and stroke, may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a study suggests. The study, “Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis,” was published recently…
The newly founded Pulmonary Wellness Foundation recently launched its interactive online 2020 Lecture Series, covering an array of topics related to respiratory health for patients, caregivers, family members, and clinicians. The free webinars are presented at 7 p.m. EST every Wednesday by the nonprofit and its founder, cardiopulmonary…
Blocking production of the enzyme JNK1 in cells lining the lungs’ airways protected mice from developing induced idiopathic pulmonary fibrosis (IPF), and almost completely reversed tissue fibrosis (scarring) in a mouse model, a study shows. The study, “Airway epithelial specific deletion of Jun-N-terminal kinase 1 attenuates…
Female sex, younger age, and a better lung function at time of diagnosis tend to support a a better overall prognosis among people with idiopathic pulmonary fibrosis (IPF), a large registry-based study reports. In contrast, the presence of pulmonary hypertension (PH), lung cancer,…
The antibiotic azithromycin (AZT), frequently prescribed for fighting bacterial infections, has anti-fibrotic effects and promotes the death of fibroblasts — cells promoting fibrosis, or scarring — in people with idiopathic pulmonary fibrosis (IPF), a new study shows. These findings suggest the potential of AZT as a therapeutic…
